Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 13 h ago

Lexeo Therapeutics, Inc.: Vestal Point Capital, LP amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Vestal Point Capital, LP amended its Schedule 13G filing on Lexeo Therapeutics, Inc., updating its beneficial ownership stake with the SEC under accession number 0000902664-26-004577. The filing, submitted under Rule 13d-1(b), indicates the investor's position in the clinical-stage gene therapy developer has changed since its prior disclosure. Lexeo focuses on genetic medicines for cardiovascular and central nervous system diseases, making institutional ownership shifts a signal of sentiment toward its pipeline. Investors will watch for further 13G or 13D amendments to gauge whether Vestal Point is accumulating or trimming its position.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Vestal Point Capital, LP, Lexeo Therapeutics, Inc.